SAFC's Dry Powder Media Manufacturing Facility in Irvine, Scotland, Officially Opens Following Extensive Validation Process
Sigma-Aldrich Corp. has announced that SAFC Commercial, the business unit providing products and services for use in regulated pharmaceutical and biopharmaceutical applications, has validated its recently expanded facility in Irvine, Scotland, which now features dry powder cell culture media.
The Irvine expansion, announced in March 2013, was initiated as part of a 5-year capital investment plan designed to support SAFC customers with critical products and services across the globe. Now fully validated, the site acts as the European counterpart to the Lenexa, Kansas, Center of Excellence for cell culture media manufacture and supply in the US.
“As the market continues to change, we’ve recommitted to staying flexible and providing exceptional support for customers, which helps reduce their risk and lowers their cost of ownership,” said Gilles Cottier, President of SAFC. “True supply redundancy and the ability to source consistent product supply in different parts of the world are key factors in providing this level of support.”
The dry powder media manufacturing capabilities added to the Irvine site are redundant to the manufacturing processes, technology and materials used at the Lenexa facility to ensure reproducible and comparable high-quality product across both sites. SAFC’s new dry powder milling and blending capabilities in Irvine are animal component-free and complementary to the liquid cell culture media, buffers and reagents that were already featured at the site.
“Irvine is one of the most modern and fit-for-purpose media facilities in the industry. With the expansion complete, SAFC is unique in its ability to support projects from early clinical development through commercial scale using a globally consistent approach across our cell culture media manufacturing sites in Irvine, Scotland; Lenexa, Kansas; and St. Louis, Missouri,” Cottier said.
The site expansion concentrated on creating shorter lead times, improving flexibility and giving customers access to real-time information. Efficiencies in throughput and responsiveness were achieved by decoupling manufacturing processes and focusing on supply logistics, while progressive technologies for in-line monitoring and a process intelligence data historian system deliver transparency. Storage capacity was also expanded, creating new material and finished goods warehousing space.
All construction work completed at the Irvine facility fully complies with appropriate FDA and EU cGMP requirements, as well as local safety and environmental regulations.
Related News
-
News Women in Pharma: Hiring Across the Gender Divide
In our monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Big Opportunity
Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe... -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News Revolutionising cancer treatment with mRNA-based therapeutics
Global market for mRNA-based oncology therapeutics expected to reach USD $2 billion by 2029, with promising results for the combination of mRNA candidates with immune checkpoint inhibitors to treat solid tumours. -
News Breaking Barriers: Innovations in Oral Solid Dose Form Bioavailability
The effectiveness of a medication often hinges on its bioavailability – the rate and extent at which the active ingredient is absorbed into the bloodstream. When it comes to oral solid dose forms, such as tablets and capsules, the challenge lies ... -
News Choosing the Right CDMO Partner: A Comprehensive Guide
Finding the right partner for the development and manufacturing of your pharmaceutical or biopharmaceutical products is paramount. This is where Contract Development and Manufacturing Organizations (CDMOs) step in, offering their expertise and infrastr...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance